Provisional T-stenting, crush, or culotte? Which is the best way to tackle bifurcation lesions? Dr Hildick-Smith presents an overview including the results of his TCT 2008 late-breaking BBC-ONE trial.
Will SYNTAX and HORIZONS-AMI change the role of DES in multivessel disease and AMI? Recorded at TCT 2008, Drs Kandzari and Bhatt each lead a case-based discussion with Drs Feres and Meredith that draws upon the latest data including these major trials.
Since our last quiz, COURAGE QoL was published, the SYNTAX trial was released... Have you been paying attention? Take our interventional cardiology quiz and find out how you rate.
As the COURAGE debate rages on, PCI and DES next tackle bypass surgery in patients with diabetes, multivessel disease and left main lesions. From ESC in Munich, Dr Boden joins SYNTAX investigators Drs Mohr and Serruys to discuss PCI and CABG in complex patients given the SYNTAX findings.
Bleeding in ACS patients has been associated with increased adverse cardiac events and negative patient outcomes. Join Drs Gilles Montalescot and Johanne Silvain as they discuss a case of bleeding and review treatment strategies to improve outcomes and minimize adverse events for these patients.
Just when you thought it was safe to go back into the cath lab, COURAGE roars again. In light of quality of life data showing that the early benefits for PCI are lost at two to three years, Drs Kandzari and Popma discuss how to optimally manage patients with stable angina.
Traditionally, Latin American countries have had lower rates of PCI and DES use compared with Europe and the US. Recorded at SOLACI 2008, Dr Leon leads an information exchange on PCI north and south of the border with Drs Abizaid, Belardi, Echeverri and Lopez-Cuellar.
Given the success of PCI, the transcatheter management of cardiac disease has expanded into new frontiers. The area of valvular intervention has rapidly evolved in recent years. Dr Philipp Bonhoeffer, a pioneer in the field, discusses current and future developments in the percutaneous management of valvular disease.
In March 2008, USA Today proclaimed that "Angioplasty's golden era may be fading." Not so fast, say interventional cardiologists in light of positive data for DES vs BMS, and the efficacy of PCI in complex settings. Drs Hamm, Rothman and Waksman discuss the state of DES/PCI in the US and Europe.
The incremental cost of DES versus BMS is balanced by reduced restenosis and improved quality of life. What level of stent thrombosis tips the scale back in favor of BMS? Join Drs Cohen and Bhatt as they discuss decision analysis data that tackles these questions.
Now you see it, now you don't. Could bioabsorbable stents be the answer to late stent thrombosis or will acute recoil and restenosis prove to be their Achilles heel? Eric Topol reviews the data on the bioabsorbable stents in development and gives his opinion on the likelihood of the disappearing stent becoming a reality.
One year post COURAGE, what's hot in the world of interventional cardiology? Dr Jeffrey Popma gives his take on the top stories from the 2008 ACC and SCAI-ACCi2 scientific sessions.
2008 will bring two new DES to the US market. Combined with recent reassuring data on long-term outcomes, will next-generation devices kick-start a comeback for DES? Drs Topol and Teirstein discuss these issues and make predictions for PCI in 2008.
Acknowledgements
CME provider: Medscape.
The drug-eluting stents theme is supported by an independent educational grant from Medtronic, Inc., Daiichi Sankyo, Inc., and Eli Lilly & Co.